ASH 2023 | Assessing the prognostic value of NGS-based MRD in adults with ALL undergoing SCT
In this video, Emily Liang, MD, Fred Hutchinson Cancer Center, Seattle, WA, discusses a retrospective study assessing the prognostic value of next-generation sequencing (NGS)-based measurable residual disease (MRD) in adult patients with acute lymphoblastic leukemia (ALL) undergoing hematopoietic stem cell transplant (SCT). Patients with detectable MRD pre-transplant and those who developed detectable MRD after transplant were at increased risk of post-transplant relapse. High concordance was found between MRD measured in bone marrow and peripheral blood samples. These findings indicate the importance of monitoring MRD in patients prior to and following transplantation to determine patients who may be at risk of relapse. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
